Pubblicazioni

Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies

2022 - EXPERT OPINION ON PHARMACOTHERAPY

Elia, G.; Ferrari, S. M.; Ragusa, F.; Paparo, S. R.; Mazzi, V.; Ulisse, S.; Benvenga, S.; Antonelli, A.; Fallahi, P.

An update on current pharmacotherapy for vulvar cancer

2022 - EXPERT OPINION ON PHARMACOTHERAPY

Bogani, Giorgio; Palaia, Innocenza; Perniola, Giorgia; Tomao, Federica; Giancotti, Antonella; Di Mascio, Daniele; Capalbo, Giuseppe; Muzii, Ludovico; Benedetti Panici, Pierluigi; Di Donato, Violante

What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?

2022 - EXPERT OPINION ON PHARMACOTHERAPY

Vanoli, F; Mantegazza, R

Advances in drug treatments for mesothelioma

2022 - EXPERT OPINION ON PHARMACOTHERAPY

Zucali, Paolo Andrea; De Vincenzo, Fabio; Perrino, Matteo; Digiacomo, Nunzio; Cordua, Nadia; D'Antonio, Federica; Borea, Federica; Fazio, Roberta; Pirozzi, Angelo; Santoro, Armando

Lurasidone in adolescents and adults with schizophrenia. from clinical trials to real-world clinical practice

2022 - EXPERT OPINION ON PHARMACOTHERAPY

Fiorillo, Andrea; Cuomo, Alessandro; Sampogna, Gaia; Albert, Umberto; CalÃ², Paola; Cerveri, Giancarlo; De Filippis, Sergio; Masi, Gabriele; Pompili, Maurizio; Serafini, Gianluca; Vita, Antonio; Zuddas, Alessandro; Fagiolini, Andrea